Wrapping up Q3 earnings, we look at the numbers and key takeaways for the healthcare technology stocks, including GoodRx ...

Key Insights Significant control over GoodRx Holdings by individual investors implies that the general public has ...

Analysts have recently evaluated GoodRx Holdings and provided 12-month price targets. The average target is $4.16, accompanied by a high estimate of $6.00 and a low estimate of $2.75. This current ...

Fintel reports that on January 22, 2026, Jefferies downgraded their outlook for GoodRx Holdings (NasdaqGS:GDRX) from Buy to ...

GoodRx Holdings Inc. (NASDAQ:GDRX) is one of the oversold stocks to buy now. On January 5, Bank of America analyst Allen Lutz lowered the firm’s price target on GoodRx to $2.60 from $3 and kept an ...

Seeking Alpha is built by investors, for investors, so you can get the insights you need to make smarter investing decisions.

Novo Nordisk oral Wegovy records 3,071 prescriptions in four days. Shares jump 6.5% as Eli Lilly oral weight loss drug awaits ...

Detailed price information for Urban Outfitters Inc (URBN-Q) from The Globe and Mail including charting and trades.

Manufacturer Novo Nordisk has partnered with telehealth companies and other weight-loss groups to increase access to the pill, starting at $149 a month ...

With prices starting at $149 for cash-paying patients, the new Wegovy pill undercuts much of the current market. Days after ...

Consumers can soon go to GoodRx for Weight Loss to determine eligibility and obtain a prescription for the first and only oral GLP-1 formulation GoodRx (Nasdaq: GDRX), the leading platform for ...

GoodRx's telemedicine service offers oral semaglutide for weight loss, with initial pricing of $149 for 1.5 mg and 4 mg doses, increasing to $199 for 4 mg after April 2026. Larger doses of oral ...